Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic

Area of Science:

• Oncolytic immunotherapy
• Cancer virology
• Immunology

Background:

• Oncolytic immunotherapies (OI) are a novel anti-cancer therapy selectively targeting cancer cells.
• Vaccinia-based OI also target tumor vasculature, reducing blood supply.
• This review explores the third mechanism: induction of active immunotherapy.

Purpose of the Study:

• To review the complementary mechanisms of action for oncolytic immunotherapies.
• To highlight the potential of OI to induce adaptive anti-tumor immunity.
• To discuss challenges and future directions in OI development.

Main Methods:

• Review of existing literature on oncolytic immunotherapies.
• Focus on vaccinia virus-based therapies.
• Analysis of immune activation mechanisms.

Main Results:

• OI have multiple mechanisms of action, including direct tumor cell lysis, targeting tumor vasculature, and inducing active immunotherapy.
• Tumors employ mechanisms to evade immune destruction.
• OI replication within tumors may overcome immune evasion and promote adaptive anti-tumor immunity.

Conclusions:

• Oncolytic immunotherapies offer a multi-pronged approach to cancer treatment.
• The induction of active immunotherapy is a critical, yet challenging, aspect of OI.
• Further understanding of OI's immune-modulating effects is crucial for optimizing cancer control, especially with agents like Pexa-Vec in clinical trials.